Middle East Ablation Devices And Diagnostic Electrophysiology Market to Surpass US$ 36.9 Million by 2028

Middle East Ablation Devices & Diagnostic Electrophysiology Market, by Product (Electrophysiology Devices (3D Mapping Systems, Electrophysiology Recording, Intracardiac Echocardiography (ICE) Ultrasound Imaging System, Radiofrequency Ablation Systems, Electrophysiology X-ray Systems, Others (Diagnostic Catheters, etc.)), and Ablation Devices (Radiofrequency Ablation, Microwave Ablation, Cryoablation, High-Intensity Focused Ultrasound, Laser Interstitial Thermal Ablation, Others (Electrical Ablation, Hydro-chemical Ablation, etc.))), by Application (Oncology, Ophthalmology, Urology, Gynaecology, Cardiovascular, and Orthopedic Radiotherapy), by End User (Hospitals, Ambulatory Surgery Centers, Specialty Centers, and Others), and by Country (UAE, Israel, Saudi Arabia, Qatar, Bahrain, Kuwait, and Rest of Middle East), is estimated to be valued at US$ 24.0 million in 2021 and is expected to exhibit a CAGR of 9.9% over the forecast period (2021-2028), as highlighted in a new report published by Coherent Market Insights.

Growing research in the field of ablation and electrophysiology devices is expected to drive the market growth over the forecast period.

For instance, in May 2017, College of Medicine and Health Services, which is affiliated with the United Arab Emirates University (UAEU), developed an innovative electrophysiology system that can be used to analyze the impact of diabetes (Type 1 and Type 2) on the heart muscle of the patient.

Middle East Ablation Devices & Diagnostic Electrophysiology Market – Impact of Coronavirus (Covid-19) Pandemic

COVID-19 outbreak was first reported on December 31, 2019, in Wuhan, China. According to the Coronavirus (COVID-19) Weekly Epidemiological Update by the World Health Organization, over 260 million cases and 5.2 million deaths due to Coronavirus (COVID-19) were reported up till November 28, 2021, across the globe.

The COVID-19 pandemic has negatively affected several markets across the globe, however, it is expected to boost demand for ablation devices & diagnostic electrophysiology. According to an article published in PubMed Central in December 2020, around 90% of critically ill COVID-19 positive patients suffer from at least one kind of ECG abnormality due to hypoxic injury, plaque rupture, myocardial injury, cytokine storm, and others. These abnormalities can be detected using cardiology electrodes, thus, COVID-19 pandemic is expected to have a positive impact on the growth of Middle East ablation devices & diagnostic electrophysiology market.

Browse 41 Market Data Tables and 30 Figures spread through 168 Pages and in-depth TOC on “T-cell Lymphoma Market”- Global Forecast to 2028, by Product (Electrophysiology Devices (3D Mapping Systems, Electrophysiology Recording, Intracardiac Echocardiography (ICE) Ultrasound Imaging System, Radiofrequency Ablation Systems, Electrophysiology X-ray Systems, and Others (Diagnostic Catheters, etc.)), and Ablation Devices (Radiofrequency Ablation, Microwave Ablation, Cryoablation, High-Intensity Focused Ultrasound, Laser Interstitial Thermal Ablation, Others (Electrical Ablation, Hydro-chemical Ablation, etc.))), by Application (Oncology, Ophthalmology, Urology, Gynaecology, Cardiovascular, and Orthopedic Radiotherapy), by End User (Hospitals, Ambulatory Surgery Centers, Specialty Centers, and Others), and by Country (UAE, Israel, Saudi Arabia, Qatar, Bahrain, Kuwait, and Rest of Middle East)

To know the latest trends and insights prevalent in the Middle East ablation devices & diagnostic electrophysiology market, click the link below:

https://www.coherentmarketinsights.com/market-insight/middle-east-ablation-devices-and-diagnostic-electrophysiology-market-4907

Key players operating in the market are focusing on adoption of inorganic growth strategies such as collaborations, acquisitions, and others, in order to strengthen their position in the Middle East ablation devices & diagnostic electrophysiology market. For instance, in November 2019, Abu Dhabi Health Services Company (SEHA), a healthcare network in the United Arab Emirates entered into a collaboration with Mayo Clinic, a non-profit global organization of academic medical centre to manage Sheikh Shakhbout Medical City, one of the UAE’s largest hospital facilities. Under this collaboration, in July 2021, Sheikh Shakhbout Medical City opened its new electrophysiology lab for diagnosis of cardiovascular conditions such as irregular heartbeat, heart attack, and others.

Key Takeaways of the Middle East Ablation Devices & Diagnostic Electrophysiology Market:

• Middle East ablation devices & diagnostic electrophysiology market is expected to exhibit a CAGR of 9.9% over the forecast period, owing to growing adoption of ablation and electrophysiology devices by end users such as hospitals, specialty centres, and others. For instance, in August 2021, Moorfields Eye Hospital, Dubai announced the addition of visual diagnostic electrophysiology to detect any visual impairment such as retina damage, macular damage, and others. Moorfields Eye Hospital also offers other electrophysiology services, including Visual evoked potential (VEP), Pattern electroretinogram (PERG), Multifocal electroretinogram (mfERG), and Electro-oculogram (EOG).
• Among application, cardiovascular is expected to account for largest market share in 2021, owing to high incidence of cardiovascular disease (CVD). For instance, according to the data provided by the World Heart Federation published in 2019, it is estimated that cardiovascular disease, a type of heart disorder is the major cause of deaths in Middle East & North Africa region causing around one third of all deaths in 2019
• Key players operating in the Middle East ablation devices & diagnostic electrophysiology market include Johnson and Johnson Private Limited, Stryker, Boston Scientific Corporation, Smith & Nephew, Biosense Webster, Inc, Abbott, Medtronic, Koninklijke Philips N.V., GE Healthcare, Siemens Healthineers, Schwarzer Cardiotek GmbH, Terumo Corporation, CathRx, Acutus Medical, and AtriCure, Inc.